AI assistant
BIO-TECHNE Corp — Director's Dealing 2019
Jul 10, 2019
30718_dirs_2019-07-10_8032cfa6-1ac4-4543-9a23-f6d0b070ff71.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BIO-TECHNE Corp (TECH)
CIK: 0000842023
Period of Report: 2019-07-08
Reporting Person: Kummeth Charles R. (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2019-07-08 | Common Stock | M | 17994.00 | $67.46 | Acquired | 110170.00 | Direct |
| 2019-07-08 | Common Stock | S | 17994.00 | $212.7478 | Disposed | 92176.00 | Direct |
| 2019-07-09 | Common Stock | M | 15037.00 | $67.46 | Acquired | 107213.00 | Direct |
| 2019-07-09 | Common Stock | S | 15037.00 | $212.432 | Disposed | 92176.00 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2019-07-08 | Stock Options (Right to buy) | $67.46 | M | 17994.00 | Disposed | 2020-04-01 | Common Stock (17994.00) | Direct |
| 2019-07-09 | Stock Options (Right to buy) | $67.46 | M | 15037.00 | Disposed | 2020-04-01 | Common Stock (15037.00) | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Restricted Stock Units | $ | Common Stock (24979.00) | 24979.00 | Direct | |
| Restricted Stock Units | $ | Common Stock (21291.00) | 21291.00 | Direct | |
| Restricted Stock Units | $ | Common Stock (16918.00) | 16918.00 | Direct | |
| Stock Option (Right to Buy) | $108.49 | 2022-08-07 | Common Stock (79517.00) | 79517.00 | Direct |
| Stock Option (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (102779.00) | 102779.00 | Direct |
| Stock Option (Right to Buy) | $106.59 | 2023-08-18 | Common Stock (154169.00) | 154169.00 | Direct |
| Stock Option (Right to Buy) | $86.25 | 2021-04-01 | Common Stock (46316.00) | 46316.00 | Direct |
| Stock Option (Right to Buy) | $67.46 | 2020-04-01 | Common Stock (65000.00) | 65000.00 | Direct |
| Stock Options (Right to buy) | $177.32 | 2025-08-08 | Common Stock (60222.00) | 60222.00 | Direct |
| Stock Options (Right to buy) | $177.32 | 2025-08-08 | Common Stock (90334.00) | 90334.00 | Direct |
| Stock Options (Right to buy) | $125.05 | 2024-08-09 | Common Stock (117342.00) | 117342.00 | Direct |
| Stock Options (Right to buy) | $125.05 | 2024-08-09 | Common Stock (78228.00) | 78228.00 | Direct |
| Stock Options (Right to buy) | $94.35 | 2021-08-12 | Common Stock (66849.00) | 66849.00 | Direct |
Footnotes
F1: Includes (i) 5,551 shares of restricted stock for which the risks of forfeiture will lapse on August 18, 2019; (ii) 9,463 shares of restricted stock for which the risks of forfeiture will lapse with respect to 4,731 shares on August 9, 2019 and as to 4,732 shares on August 9, 2020; and (iii) 11,279 shares of restricted stock for which the risk of forfeiture will lapse as to 3,760 shares on August 8, 2019 and August 8, 2020 and as to 3,759 shares on August 8, 2021.
F2: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2019 and amended on June 7, 2019.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $214.125, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $212.00 to $213.58, inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5: Fully exercisable
F6: Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
F7: Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F8: Vests in full or in part on 8/9/2020 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F9: Vests in full or in part on 8/8/2021 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
F10: Vests 19,879 shares on each of 8/7/16, 8/7/17 and 8/7/18 and 19,880 shares on 8/7/19.
F11: Vests 25,695 shares on each of 8/18/17, 8/18/18, and 8/18/19 and 25,694 shares on 8/18/20.
F12: Vests 15,056 shares each on 8/8/2019, 8/8/202 and 15,055 shares each on 8/8/2021, 8/8/2022
F13: Vests 19,557 each on 8/9/2018, 8/9/2019, 8/9/2020, 8/9/2021